Traveller vaccination human papillomavirus: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''To read more about human papillomavirus, click [[Human papillomavirus|here]].''' | |||
__NOTOC__ | __NOTOC__ | ||
{{Traveller vaccination | {{Traveller vaccination}} | ||
{{CMG}};{{AE}}{{MehdiP}} | {{CMG}};{{AE}}{{MehdiP}} | ||
==Overview== | ==Overview== | ||
Protection against human papillomavirus is not specific to the needs of most travellers. In many countries vaccine against human papillomavirus is routinely administered in childhood. Before travelling, missing vaccinations in young girls should be offered according to national recommendations. | Protection against human papillomavirus is not specific to the needs of most travellers. In many countries vaccine against human papillomavirus is routinely administered in childhood. Before travelling, missing vaccinations in young girls should be offered according to national recommendations. | ||
==Disease cause== | ==Disease cause== | ||
Human papillomavirus (HPV) | [[Human papillomavirus]] (HPV) | ||
==Transmission== | ==Transmission== | ||
Sexual contact | Sexual contact | ||
==Nature of the disease== | ==Nature of the disease== | ||
HPV mostly causes transient benign mucosal infection but it can develop to anogenital precancerous conditions and cancers. Some genotypes of HPV may cause anogenital warts and recurrent respiratory papillomatosis. | [[HPV]] mostly causes transient benign [[mucosal]] infection but it can develop to [[Perineum|anogenital]] precancerous conditions and cancers. Some genotypes of [[Human papillomavirus|HPV]] may cause anogenital warts and recurrent [[respiratory papillomatosis]]. | ||
==Geographical distribution== | ==Geographical distribution== | ||
HPV is prevalent globally. The incidence of cervical cancer is highest in Latin America and the Caribbean, sub-Saharan Africa, Melanesia, and southern Asia. | HPV is prevalent globally. The incidence of cervical cancer is highest in Latin America and the Caribbean, sub-Saharan Africa, Melanesia, and southern Asia. | ||
| Line 16: | Line 18: | ||
==Vaccine== | ==Vaccine== | ||
Two vaccines against HPV infection are available. | Two vaccines against HPV infection are available. | ||
*Bivalent (2 genotypes); 2 doses protect against genital cancer. | *Bivalent (2 genotypes); 2 doses protect against [[genital cancer]]. | ||
*Tetravalent (4 genotypes); 3 doses protect against genital cancers and warts. | *Tetravalent (4 genotypes); 3 doses protect against [[Genital cancer|genital cancers]] and [[warts]]. | ||
The vaccines are intended primarily for girls 9-14 years of age. | The vaccines are intended primarily for girls 9-14 years of age. | ||
Latest revision as of 19:01, 24 April 2017
To read more about human papillomavirus, click here.
|
Traveler Vaccination |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]
Overview
Protection against human papillomavirus is not specific to the needs of most travellers. In many countries vaccine against human papillomavirus is routinely administered in childhood. Before travelling, missing vaccinations in young girls should be offered according to national recommendations.
Disease cause
Human papillomavirus (HPV)
Transmission
Sexual contact
Nature of the disease
HPV mostly causes transient benign mucosal infection but it can develop to anogenital precancerous conditions and cancers. Some genotypes of HPV may cause anogenital warts and recurrent respiratory papillomatosis.
Geographical distribution
HPV is prevalent globally. The incidence of cervical cancer is highest in Latin America and the Caribbean, sub-Saharan Africa, Melanesia, and southern Asia.
Risk for travellers
Transmission of HPV occurs most commonly through sexual activity.
Vaccine
Two vaccines against HPV infection are available.
- Bivalent (2 genotypes); 2 doses protect against genital cancer.
- Tetravalent (4 genotypes); 3 doses protect against genital cancers and warts.
The vaccines are intended primarily for girls 9-14 years of age.